NSP · Insperity, Inc · Stock research

• # NSP — Insperity, Inc.

Current Thesis

The binary this name was gated on has resolved. The 2026-07-29 Q2 print beat on both lines — adjusted EPS $0.34 versus $0.32 consensus, revenue $1.686B versus $1.672B — and, more consequential for a professional employer organization whose only volume metric is average paid worksite employees (WSEEs), the FY2026 WSEE guide floor was lifted to 305,000–307,000 from the prior 303,000–307,000. Q2 WSEEs printed 305,764 against 303,049 in Q1 2026. Full-year adjusted-EBITDA guidance narrowed and its floor rose, to $185–225M from $170–230M. Price responded: a 52-week high of $54.03 in the trailing window, with the 2026-08-14 close at $52.20, 3.4% below it, after a 75.8% three-month return. The leg an investor is buying is margin repair converting into a raised full-year floor while the employee base stops deteriorating. What is not yet in the numbers is any disclosed revenue from the Workday HRScale partnership, which still shows up only as cost: $8M in Q2, $16M year-to-date.

Bullish and bearish views on Insperity, Inc

The model's bull view on Insperity, Inc (NSP), in brief: The guide floor went up, not down. FY2026 WSEE guidance moved to 305,000–307,000 on 2026-07-29 from 303,000–307,000 issued with the Q1 print on 2026-05-01. The specific bear condition flagged before the print — a second consecutive worksite-employee guide cut — did not occur.… The bear view: Q3 guidance is below the Street on both measures. Both cases follow in full.

Bull Case

• The guide floor went up, not down. FY2026 WSEE guidance moved to 305,000–307,000 on 2026-07-29 from 303,000–307,000 issued with the Q1 print on 2026-05-01. The specific bear condition flagged before the print — a second consecutive worksite-employee guide cut — did not occur.
• Margin repair is showing in the operating line. Q2 2026 adjusted EBITDA $36M, +13% YoY. FY2026 adjusted EBITDA guidance $185–225M implies +41% to +72% YoY; FY adjusted EPS guidance $1.88–$2.43 versus $2.05 consensus, narrowed from $1.60–$2.60.
• GAAP range tightened around a positive number. FY2026 GAAP EPS guidance narrowed to $0.76–$1.31 from $0.48–$1.48 (consensus $0.92), reported 2026-07-29 — the first full-year GAAP range in this cycle whose low end is meaningfully profitable.
• Sequential volume stabilized. 303,049 average paid WSEEs in Q1 2026 to 305,764 in Q2 2026. PEO headcount is seasonal, so one sequential quarter is not a trend, but it is the first move in the right direction since the drawdown.
• Street targets reset upward after the print. Roth to $59 from $54 (Buy) and Baird to $56 from $36 (Neutral), both reported following the 2026-07-29 report; Truist raised to $52 from $35 (Hold) on 2026-07-22. All three sit at or above the 2026-08-14 close of $52.20.

Bear Case

• Q3 guidance is below the Street on both measures. Q3 2026 adjusted EPS guided $(0.09)–$0.41 against $0.23 consensus; Q3 GAAP EPS $(0.32)–$0.18 against $0.01 consensus; Q3 adjusted EBITDA $14–41M. A range spanning a loss and a solid quarter is an admission of limited forward visibility on benefits cost.
• Gross profit is still contracting. Q2 2026 gross profit $217M, -3% YoY, while revenue rose 2% to $1.686B. Revenue growth came from revenue per WSEE per month, up 3% — pricing carrying a shrinking volume base.
• The full year still guides to a decline. 305,000–307,000 average paid WSEEs implies -1.0% to -1.6% versus 2025. A PEO with a shrinking worksite headcount has no organic volume engine.
• HRScale remains unquantified in filings. The Workday strategic partnership cost $8M in Q2 2026 and $16M year-to-date with no disclosed client count or partnership revenue. The $500M-plus incremental-revenue-by-2028 framing is management ambition that no reported line yet tests.
• Capital return did not lean into the drawdown. Year-to-date through Q2 2026: roughly 172,000 shares repurchased for $4M, against $46M of dividends paid. The buyback was near-dormant through a period when the stock traded far below current levels.
• The structural exposure is unchanged. Insperity carries health-benefit costs for its clients; medical cost inflation is what produced the 2025 collapse to a $18.57 low, and nothing in the Q2 disclosure removes that mechanism.

Setup & Price Structure

• Close $52.20 on 2026-08-14, 3.4% under the $54.03 52-week high, RSI(14) 54.6, three-month return +75.8%. Momentum has cooled to mid-range while price holds near the high — consolidation under resistance rather than an extended vertical tape.
• The narrative is accelerating, dated to the 2026-07-29 guide raise and the price-target resets that followed within days. Baird's move from $36 to $56 in one revision is the clearest marker that sell-side models are being rebuilt, not merely tweaked. The flip to maturing would be visible when target revisions stop arriving while price ranges below $54.
• Crowding and positioning observables: analyst coverage is thin — roughly four to five firms — and the aggregated rating remains Neutral even after the raises, so published consensus is one revision away from moving. The target raises arrived after the move, not ahead of it. No earnings date falls inside the next 30 days; the Q3 print is expected late October. Capital return is dividend-weighted ($46M YTD) with a $4M YTD buyback. No insider-sale or equity-issuance disclosure has surfaced in the trailing 30 days.
• Reference structure: the pre-print consolidation area sat near $48 (the shares traded around $48.35 on 2026-07-24). The post-print advance to $54.03 sits entirely above that shelf; losing it on a weekly basis would return price inside the pre-earnings range.

Catalyst Calendar (next 30 days)

• ~2026-09-02 (est.) — ADP National Employment Report for August. The small-establishment series is the closest public read on the hiring behaviour of the SMB cohort that supplies Insperity's WSEE count between prints.
• 2026-09-04 (est.) — August BLS employment situation. Same read-through, broader sample.
• ~2026-09-08 (est.) — NFIB Small Business Optimism (August), including hiring plans — the forward-looking component of the same signal.
• ~2026-10-27 (est.) — Q3 2026 results. Outside the 30-day window, and the next hard binary: the company has already published a Q3 adjusted-EBITDA range of $14–41M and a WSEE range of 305,500–307,500, so both the beat/miss and the volume trend are pre-framed.

Elapsed catalysts

• ~2026-08-19 (est.) — quarterly dividend declaration. The last declaration was 2026-05-20 at $0.60 per share; a repeat confirms the $2.40 annualized run-rate that a meaningful part of the shareholder base is present for. (passed 7d ago)

What Would Change Our Mind

• The post-print structure is what carries the thesis: the advance since 2026-07-29 has held above the late-July consolidation near $48. A weekly close below $46 gives that back entirely and reads as a failed re-rating rather than a pullback.
• On fundamentals, a Q3 average-paid-WSEE print below the 305,500 guide floor, or an FY2026 adjusted-EBITDA guide cut back under $185M, would say the two things that improved on 2026-07-29 did not hold.
• On the growth leg, if the ~2026-10-27 print passes with partnership costs rising again and still no disclosed HRScale client count, the optionality stays a slide deck and the equity is a margin-repair story attached to a declining volume base.
• A flip to saturated would look like clustered retail-sentiment coverage plus a batch of upgrades to Buy near $54 with no new WSEE datapoint underneath them.

Correlation Notes

• TriNet (TNET) is the closest listed comparable — same PEO volume dynamic, same health-benefit pass-through. Its quarterly WSEE disclosure is an external check on whether the Q2 sequential stabilization here was company-specific or industry-wide.
• Paychex (PAYX) and ADP track the same SMB payroll volumes with far less benefits-cost carry, so a divergence between their client-employment commentary and Insperity's WSEE trend isolates the PEO-specific piece.
• Workday (WDAY) is the HRScale partner; co-sell commentary on WDAY's calls is one of the few third-party windows into traction while Insperity discloses cost only.
• Managed-care loss-ratio commentary (UNH, ELV, CI) leads the medical-trend input that broke the 2025 P&L; an acceleration there precedes gross-profit pressure here.
• As a thinly covered small-cap, non-news-day movement tracks Russell 2000 risk appetite more than anything company-specific.